{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:12:22Z","timestamp":1788426742138,"version":"build-2803163510"},"reference-count":5,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ad.2026.104665","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:45:04Z","timestamp":1776383104000},"page":"104665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to Martorell Calatayud et al., \u201cCost-Consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-Severe Hidradenitis Suppurativa\u201d"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6134-5155","authenticated-orcid":false,"given":"J.","family":"Roman\u00ed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2026.104665_bib0030","article-title":"Cost-consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-severe Hidradenitis Suppurativa","volume":"117","author":"Martorell","year":"2025","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2026.104665_bib0035","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2026.104665_bib0040","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE)","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2026.104665_bib0045","unstructured":"Plataforma de Contrataci\u00f3n del Sector P\u00fablico. Precios de adquisici\u00f3n de medicamentos biol\u00f3gicos en el SNS espa\u00f1ol. https:\/\/contrataciondelestado.es\/wps\/wcm\/connect\/PLACE_es\/Site\/area\/docAccCmpnt?srv=cmpnt&cmpntname=GetDocumentsById&source=library&DocumentIdParam=39a358c3-6656-4a21-93e8-24bb0a4d4af4 Accessed 4.1.26."},{"key":"10.1016\/j.ad.2026.104665_bib0050","unstructured":"https:\/\/www.sanidad.gob.es\/areas\/farmacia\/precios\/comisionInteministerial\/acuerdosNotasInformativas\/docs\/ACUERDOS_CIPM_243.pdf Accessed 4.1.26."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173102600075X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173102600075X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T08:15:02Z","timestamp":1788423302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000173102600075X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":5,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S000173102600075X"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2026.104665","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to Martorell Calatayud et al., \u201cCost-Consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-Severe Hidradenitis Suppurativa\u201d","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2026.104665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"104665"}}